MA54503A - Arn codant pour une protéine - Google Patents

Arn codant pour une protéine

Info

Publication number
MA54503A
MA54503A MA054503A MA54503A MA54503A MA 54503 A MA54503 A MA 54503A MA 054503 A MA054503 A MA 054503A MA 54503 A MA54503 A MA 54503A MA 54503 A MA54503 A MA 54503A
Authority
MA
Morocco
Prior art keywords
protein
rna coding
rna
coding
Prior art date
Application number
MA054503A
Other languages
English (en)
Inventor
Friedrich Metzger
Hervé Schaffhauser
Justin Antony Selvaraj
Original Assignee
Versameb Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versameb Ag filed Critical Versameb Ag
Publication of MA54503A publication Critical patent/MA54503A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA054503A 2018-12-19 2019-12-18 Arn codant pour une protéine MA54503A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18214221 2018-12-19
EP19208066 2019-11-08

Publications (1)

Publication Number Publication Date
MA54503A true MA54503A (fr) 2021-10-27

Family

ID=68848313

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054503A MA54503A (fr) 2018-12-19 2019-12-18 Arn codant pour une protéine

Country Status (19)

Country Link
US (1) US20220002364A1 (fr)
EP (1) EP3898982A2 (fr)
JP (2) JP2022514863A (fr)
KR (1) KR20210105382A (fr)
CN (2) CN113454227B (fr)
AU (1) AU2019407921A1 (fr)
BR (1) BR112021011771A2 (fr)
CA (1) CA3120638A1 (fr)
CL (1) CL2021001571A1 (fr)
CO (1) CO2021007916A2 (fr)
IL (1) IL284035A (fr)
MA (1) MA54503A (fr)
MX (1) MX2021007241A (fr)
PE (1) PE20211342A1 (fr)
PH (1) PH12021551135A1 (fr)
SG (1) SG11202105267VA (fr)
TW (1) TW202043477A (fr)
WO (1) WO2020127532A2 (fr)
ZA (1) ZA202104912B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (fr) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de troubles métaboliques et de maladies cardiovasculaires avec des inhibiteurs de la sous-unité bêta e de l'inhibine (inhbe)
US20240374507A1 (en) * 2021-01-26 2024-11-14 Sigilon Therapeutics, Inc. Compositions, devices and methods for inducing antigen-specific immune tolerance
CN118076748A (zh) * 2021-03-01 2024-05-24 约翰·霍普金斯大学 通过自组装蛋白质进行分子索引(mipsa)以实现高效的蛋白质体学研究
WO2022216944A1 (fr) * 2021-04-07 2022-10-13 Mayo Foundation For Medical Education And Research Procédés et matériaux d'inversion de l'instabilité de la plaque d'athérome
AU2022262176A1 (en) * 2021-04-19 2023-11-02 Versameb Ag Method of treating lower urinary tract symptoms
AU2022299474A1 (en) * 2021-06-23 2023-12-21 Versameb Ag Compositions and methods for modulating expression of genes
CN115992146B (zh) * 2022-11-11 2025-04-18 上海交通大学医学院附属第九人民医院 经修饰的mRNA分子及相关产品和用途
WO2024189146A1 (fr) * 2023-03-15 2024-09-19 Versameb Ag Arn codant pour une protéine
CN116676335A (zh) * 2023-05-15 2023-09-01 武汉大学 Chrdl1基因敲入小鼠模型及其构建方法
CN120400195B (zh) * 2024-05-14 2025-09-30 赛德特生物制药有限公司 一类改构的截短型il-24序列及其在治疗肿瘤中的应用
CN120209114B (zh) * 2025-03-07 2026-04-07 首都医科大学 一种含有penk蛋白的组合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274314C (fr) * 1996-12-02 2007-03-13 Genemedicine, Inc. Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation
WO2002096356A2 (fr) * 2001-05-25 2002-12-05 Cornell Research Foundation, Inc. Ligand a forte affinite pour le recepteur de la neurotrophine p75
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
JP4451036B2 (ja) * 2001-11-30 2010-04-14 生化学工業株式会社 新規コンドロイチン合成酵素
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1971401A2 (fr) * 2005-12-22 2008-09-24 EMBL (European Molecular Biology Laboratory) PROCEDES D'UTILISATION DU VARIANT DE CALCINEURINE A Cnaß1
WO2009146183A1 (fr) * 2008-04-15 2009-12-03 Genzyme Corporation Procédés de production du facteur rdcvf
AU2010227419A1 (en) * 2009-03-27 2011-10-20 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
CN102971002B (zh) * 2010-07-09 2019-04-05 国立大学法人东京大学 核酸递送用组合物及载体组合物、使用其的药物组合物以及核酸递送方法
HRP20181315T1 (hr) * 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
CN110777124A (zh) * 2011-10-27 2020-02-11 威尔斯达眼科制剂公司 编码视杆细胞来源的视锥细胞活力因子的载体
US9994829B2 (en) * 2012-07-02 2018-06-12 Iprogen Biotech, Inc. Intracellular protein delivery
SG11201607519VA (en) * 2014-03-14 2016-10-28 Genentech Inc Methods and compositions for secretion of heterologous polypeptides
WO2015162930A1 (fr) * 2014-04-24 2015-10-29 一般社団法人 医療産業イノベーション機構 Procédé permettant d'améliorer l'expression des protéines, et composition pour l'expression des protéines
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
GB201705484D0 (en) * 2017-04-05 2017-05-17 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
SG11202105267VA (en) 2021-07-29
TW202043477A (zh) 2020-12-01
PH12021551135A1 (en) 2022-02-28
CL2021001571A1 (es) 2022-04-18
CN113454227B (zh) 2025-05-23
CO2021007916A2 (es) 2021-09-20
US20220002364A1 (en) 2022-01-06
BR112021011771A2 (pt) 2021-08-31
IL284035A (en) 2021-08-31
JP2022514863A (ja) 2022-02-16
JP2024156665A (ja) 2024-11-06
PE20211342A1 (es) 2021-07-26
CA3120638A1 (fr) 2020-06-25
ZA202104912B (en) 2025-10-29
WO2020127532A2 (fr) 2020-06-25
WO2020127532A3 (fr) 2020-09-17
MX2021007241A (es) 2021-09-23
EP3898982A2 (fr) 2021-10-27
AU2019407921A1 (en) 2021-06-10
KR20210105382A (ko) 2021-08-26
CN120519489A (zh) 2025-08-22
CN113454227A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
IL285152A (en) Predicting three-dimensional features for autonomous driving
EP3939251A4 (fr) Codage de contexte pour mode de saut de transformée
EP3981082A4 (fr) Pré-codage géométrique réciproque
IL284035A (en) RNA encodes a protein
EP3610630A4 (fr) Interface logicielle pour contrats intelligents
EP3386530A4 (fr) Peptides pour thérapie rénale
IL280400A (en) Nucleic acids encode enhanced transaminase proteins
EP3813234A4 (fr) Armature
EP4081547A4 (fr) Nouveaux anticorps anti-fgfr2b
EP3638789A4 (fr) Arn guides conditionnels
EP4058710A4 (fr) Raccord renforcé
EP4081539A4 (fr) Nouveaux anticorps anti-fgfr2b
EP4037794C0 (fr) Bloc empilable
DK3840767T5 (da) Peptider
EP4048213A4 (fr) Injecteur intravitréen
PT3806660T (pt) Barra proteica
IL292799A (en) Anti-siglec-9 antibody molecules
EP3644198C0 (fr) Conception 3d de peau b-rep
EP3753553C0 (fr) Imprimante 3d
EP4041854C0 (fr) Adoucissant pour tissus
EP4041855C0 (fr) Adoucissant pour tissus
EP3939997A4 (fr) Anticorps anti-podoplanine
EP3882935A4 (fr) Transformateur pour véhicules
IL285757A (en) Three-dimensional nano-patterns
DK4025612T3 (da) Anti-fukosyl-gm1-antistoffer